Intellia Therapeutics, Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.73
Forward P/E Ratio
-9.01
PEG Ratio
0.14
-4.53
Price-to-Sales (TTM)
32.64
3.00
5.16
Market Cap
1.99B
1.86B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-3.23
-56.34%
66.09M
Is it growing?
-9.50%
-9.50%
Is it risky?
1.77
12.96
6.10
80.49M
Who owns it?
76.90%
3.88%
45.40%
120.45M
134.00M
Does it pay?
0.00%
0.00%
--
--
How much cash?
375.99M
-363.15M
-235.23M
2.69
- Price
- 14.22
- Percent Change
- -1.23 (7.93%)
- Previous Close
- 15.44
- Open
- 15.47
- Low
- 14.11
- High
- 15.49
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$14.22
From 52W Low
+78.81%
From 52W High
-49.68%
Today
-7.93%
1Y Change
+18.95%
6M
$11.43
3M
$14.26
1M
$12.11
Today
$14.22
From 52W Low
+78.81%
From 52W High
-49.68%
Today
-7.93%
1Y Change
+18.95%
6M
$11.43
3M
$14.26
1M
$12.11
Today
$14.22
Below Average
within its 1-year price range
$14.22
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+17.4%
3M
-0.3%
6M
+24.4%
1Y
+19.0%
Rate of Change (ROC)
Accelerating
Price is rising 9.7x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Intellia Therapeutics, Inc.
- Founded
- 2014
- CEO
- John M. Leonard
- Employees
- 403
- Fiscal Year End
- Dec 31, 2024
- Address
57 Cambridge Parkway, Suite 200A
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.intelliatx.com
Indicators
Operating Cash Flow
-363.15M
Net Income
-394.60M
Backed by Cash
0.92
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
Cathie WoodPortfolio ARK Investment Management |
Indicators
Operating Cash Flow
-363.15M
Net Income
-394.60M
Backed by Cash
0.92
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-3.73
Forward P/E Ratio
-9.01
PEG Ratio
0.14
-4.53
Price-to-Sales (TTM)
32.64
3.00
5.16
Market Cap
1.99B
1.86B
Is it profitable?
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
0.00%
Diluted EPS (TTM)
-3.23
-56.34%
66.09M
Is it growing?
-9.50%
-9.50%
Is it risky?
1.77
12.96
6.10
80.49M
Who owns it?
76.90%
3.88%
45.40%
120.45M
134.00M
Does it pay?
0.00%
0.00%
--
--
How much cash?
375.99M
-363.15M
-235.23M
2.69
- Price
- 14.22
- Percent Change
- -1.23 (7.93%)
- Previous Close
- 15.44
- Open
- 15.47
- Low
- 14.11
- High
- 15.49
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$14.22
From 52W Low
+78.81%
From 52W High
-49.68%
Today
-7.93%
1Y Change
+18.95%
6M
$11.43
3M
$14.26
1M
$12.11
Today
$14.22
From 52W Low
+78.81%
From 52W High
-49.68%
Today
-7.93%
1Y Change
+18.95%
6M
$11.43
3M
$14.26
1M
$12.11
Today
$14.22
Below Average
within its 1-year price range
$14.22
Multi-Timeframe Analysis (MTA)
Uptrend
Most timeframes point up. One conflicting period introduces some uncertainty, but the overall direction is positive. Weaker than a Strong Uptrend, but still a bullish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
+17.4%
3M
-0.3%
6M
+24.4%
1Y
+19.0%
Rate of Change (ROC)
Accelerating
Price is rising 9.7x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Intellia Therapeutics, Inc.
- Founded
- 2014
- CEO
- John M. Leonard
- Employees
- 403
- Fiscal Year End
- Dec 31, 2024
- Address
57 Cambridge Parkway, Suite 200A
Cambridge
Massachusetts
02142
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.intelliatx.com
Related Heatmaps
Cathie WoodPortfolio ARK Investment Management |